MedTrace Logo

Exploration of the Cellular and Molecular Mechanisms in Patients Receiving Biotherapies Targeting the IL-23/IL-17 Axis in Cutaneous Psoriasis

NCT05111210 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2025-05-14

No results posted yet for this study

Summary

This is a research study involving humans, of the interventional type with minimal risks and constraints (RIPH2). It is a monocentric, non randomized prospective study aiming to better understand the mechanisms of the response to anti-IL-23 biologics in psoriasis patients attending the dermatology department of hospital Cochin (APHP).

Conditions

Interventions

OTHER

Blood sample

Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed

OTHER

Data collection

collection of socio-demographic, clinical and biological data.

OTHER

skin biopsies

skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds

Sponsors & Collaborators

  • Janssen Biotech, Inc.

    collaborator INDUSTRY

  • Institut Pasteur

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-14
Primary Completion
2028-06-30
Completion
2028-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05111210 on ClinicalTrials.gov